A Study of Dapansutrile Plus Pembrolizumab in Patients with PD-1 Refractory Advanced Melanoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Olatec Therapeutics LLC
Start Date
August 10, 2022
End Date
August 14, 2027
Administered By
Duke Cancer Institute
Awarded By
Olatec Therapeutics LLC
Start Date
August 10, 2022
End Date
August 14, 2027